Is Trevi Therapeutics, Inc. (TRVI) a Buy, Sell, or Hold?
Trevi Therapeutics, Inc.
NASDAQ:TRVI
$18.145 USD
$0.23 (1.31%)
- Volume
- 1.89M
- Average Volume
- 1.95M
- Market Capitalization
- $2.58B
- P/E Ratio
- -56.32
- Dividend Yield
- 0.00%
- Price Target
- $25.00
- Year High
- $20.15
- Year Low
- $6.55
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $24.75
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jennifer L. Good |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | TRVI |
| CUSIP | 89532M101 |
| CIK | 0001563880 |
| Web | https://www.trevitherapeutics.com |
| Phone | 203 304 2499 |
| Currency | USD |
| Employees | 34 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 24.75 |
| Quick Ratio | 24.75 |
| Cash Ratio | 2.73 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.22 |
| Price / Cash Flow | -80.66 |
| Price / Book | 15.35 |
Price Target and Rating
| Average Stock Price Forecast | $25.00 |
| High Stock Price Forecast | $30.00 |
| Low Stock Price Forecast | $20.00 |
| Forecast Upside/Downside | -27.42% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 17 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.29 |
| Trailing P/E Ratio | -56.32 |
| PEG Ratio | -1.59 |
| P/E Growth | -1.59 |
| Net Income | $-42.76M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -24.53% |
| Return on Assets | -25.40% |
Financials Score
| AltmanZ Score | 185.78 |
| Piotroski Score | 2.00 |
| Working Capital | 169.01M |
| Total Assets | 179.61M |
| Ebit | -45.68M |
| Market Cap | 2.35B |
| Total Liabilities | 7.48M |
Poll Results
About Trevi Therapeutics, Inc. (NASDAQ:TRVI) Stock
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut. ...
Trevi Therapeutics Announces Upcoming June and July Event Schedule
2026-06-17 07:30:00
NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will attend several upcoming events in June and July.
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
2026-06-03 09:44:22
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.
2026-05-12 22:10:55
Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030
2026-05-09 05:07:16
Trevi Therapeutics NASDAQ: TRVI outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming clinical trial starts, a specialty commercial strategy and an extended cash runway following a recent financing.
Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript
2026-05-06 06:01:51
Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-05 16:05:00
Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough and continued pipeline advancement Clinical development plans remain on track across all chronic cough indications Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn.
2026-04-30 16:05:00
Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyses by baseline cough count and background anti-fibrotic use An exploratory post-hoc analysis of the effects of nalbuphine ER and placebo on cough bouts from the Phase 2b CORAL trial in patients with IPF-related chronic cough and the Phase 2a RIVER trial in patients with refractory chronic cough Drug–drug interaction data from a Phase 1 study evaluating pharmacokinetics and safety following co-administration of nalbuphine ER with pirfenidone or nintedanib NEW HAVEN, Conn., April 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that it will deliver an oral presentation and present multiple abstracts at the American Thoracic Society (ATS) 2026 International Conference, taking place from May 15 – 20, 2026, in Orlando, Florida.
2026-04-28 16:05:00
NEW HAVEN, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, May 5, 2026, at 4:30 p.m.
Frequently Asked Questions
-
What is the current Trevi Therapeutics, Inc. (TRVI) stock price?
-
Trevi Therapeutics, Inc.(NASDAQ:TRVI) stock price is $18.145 in the last trading session. During the trading session, TRVI stock reached the peak price of $20.15 while $6.55 was the lowest point it dropped to. The percentage change in TRVI stock occurred in the recent session was 1.31% while the dollar amount for the price change in TRVI stock was $0.23.
-
TRVI's industry and sector of operation?
-
The NASDAQ listed TRVI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of TRVI?
-
Jennifer L. Good | Co-Founder, Chief Executive Officer, President & Director
Thomas R. Sciascia | Co-Founder & Chief Scientific Officer
David C. Hastings | Chief Financial Officer & Principal Financial Officer
Farrell Simon | Chief Commercial Officer
Katherine Takaki | Senior Vice President of Global Regulatory Affairs -
How many employees does TRVI have?
-
Number of TRVI employees currently stands at 34. TRVI operates from 195 Church Street, New Haven, CT 06510, US.
-
Link for TRVI official website?
-
Official Website of TRVI is: https://www.trevitherapeutics.com
-
How do I contact TRVI?
-
TRVI could be contacted at phone #203 304 2499 and can also be accessed through its website. TRVI operates from 195 Church Street, New Haven, CT 06510, US.
-
How many shares of TRVI are traded daily?
-
The average number of TRVI shares traded daily for last 3 months was 1.95M.
-
What is the market cap of TRVI currently?
-
The market value of TRVI currently stands at $2.58B with its latest stock price at $18.145